CSL share price on watch amid US$1.6b profit

CSL has been battling currency headwinds during the half but still delivered a solid result…

| More on:
A doctor appears shocked as he looks through binoculars on a blue background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • CSL has released its half year results this morning
  • The biotherapeutics giant has delivered a US$1.6 billion profit
  • Management has reaffirmed its full year profit guidance

The CSL Limited (ASX: CSL) share price will be one to watch on Tuesday.

This follows the release of the biotherapeutics giant's eagerly anticipated half year results.

CSL share price on watch following results release

  • Total revenue up 19% to US$7,183.5 million
  • Net profit after tax down 8% to US$1,623.2 million
  • Net profit after tax before amortisation (NPATA) in constant currency up 10% to US$1,957 million
  • Interim dividend up 2.9% to US$1.07 per share

What happened during the half?

For the six months ended 31 December, CSL reported a 19% increase in total revenue to US$7,183.5 million.

This was driven by the acquisition of Vifor Pharma, strong growth in immunoglobulin and albumin sales, record levels of plasma collections, strong growth in market leading haemophilia B product Idelvion and key specialty product Kcentra, and a strong performance by influenza vaccines business, CSL Seqirus.

And while CSL's profits were down 8% to US$1,623.2 million, this was in line with consensus estimates and due to currency headwinds and acquisition costs. This was largely.

NPATA on a constant currency basis provides a better reflection of the company's performance. That was up 10% year over year to US$1,957 million.

Management commentary

CSL's outgoing CEO, Paul Perreault, commented:

CSL delivered a solid performance in the first half of the financial year demonstrating the strong fundamentals of the company and the disciplined execution of our patient focused strategy. Our focused investment across our business units underpinned our resilience throughout the pandemic, and as we emerge from it we are starting to deliver positive momentum behind our sustainable growth agenda.

Outlook

Management is expecting more of the same in the second half. As a result, it has reaffirmed its guidance for FY 2023 NPATA in the range of approximately US$2.7 billion to US$2.8 billion at constant currency. Perreault added:

The strong growth we have seen in plasma collections and our immunoglobulins franchise is expected to continue. We are looking forward to launching Hemgenix in the US, an exciting, ground breaking, new therapy that will change people's lives. The rest of our R&D pipeline is in great shape and we look forward to bringing more innovative therapies to patients in the future.

Seqirus continues to perform strongly and will deliver another profitable year. Consistent with the seasonal nature of the business we anticipate, however, a loss in the second half of the year. The integration of CSL Vifor is well advanced and we will focus on driving organic growth and efficiencies across the product portfolio and deliver on our synergy objectives

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a young scientist using a digital tablet while working in a lab.
Share Gainers

If you'd put $20,000 in this ASX healthcare stock during COVID-19, you'd have $257,000 now

You could have become filthy rich in just 4 years. Just think about that.

Read more »

Shot of a young scientist using a laptop while conducting research in a laboratory.
Healthcare Shares

Sonic Healthcare shares hit 52-week low as analysts take a scalpel to targets

Analysts have sharpened the knives after the latest blood-sucking half year at Sonic Healthcare.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
52-Week Highs

Medibank share price hits 52-week high on US tech partnership

This private health insurer's shares are scaling new heights today. But why?

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

What is the dividend growth rate of CSL stock?

CSL's dividends are worth more than what meets the eye.

Read more »

Shot of a young scientist looking stressed out while working on a computer in a lab.
Earnings Results

Sonic share price sinks after first-half profit crash

The healthcare company's profits have almost halved.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

The market is placing 'zero value' on this ASX 200 stock's booming pipeline

Up 78% in a year, these experts reckon there’s more outperformance to come from this top ASX 200 stock.

Read more »

Shot of a senior scientist looking stressed out while working in a lab.
Healthcare Shares

This ASX 200 healthcare share is diving 13% as short sellers take aim

A short seller is describing this company's Daybue product as a 'flop'.

Read more »

Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
Healthcare Shares

Guess which ASX 300 healthcare stock is surging 13% on FDA news

Here's what's getting investors excited today.

Read more »